Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$306K Sell
5,551
-204
-4% -$11.1K 0.2% 54
2025
Q4
$282K Buy
5,755
+54
+0.9% +$2.52K 0.19% 58
2025
Q3
$246K Sell
5,701
-124
-2% -$4.84K 0.18% 66
2025
Q2
$224K Buy
5,825
+76
+1% +$2.9K 0.17% 68
2025
Q1
$223K Sell
5,749
-364
-6% -$13.3K 0.18% 67
2024
Q4
$207K Buy
6,113
+50
+0.8% +$1.8K 0.17% 69
2024
Q3
$248K Sell
6,063
-1,002
-14% -$41K 0.19% 65
2024
Q2
$272K Sell
7,065
-683
-9% -$28.7K 0.23% 56
2024
Q1
$332K Buy
7,748
+469
+6% +$19.3K 0.27% 48
2023
Q4
$270K Buy
+7,279
New +$261K 0.25% 54

Other funds holding GSK

Bruce G. Allen Investments's GSK Position: Q1 2026 in Review

Bruce G. Allen Investments reduced its GSK (GSK) stake by 3.5% in Q1 2026, selling an estimated $11.1K and leaving 5,551 shares worth $306K. The position accounts for 0.2% of the portfolio, ranked #54.

Bruce G. Allen Investments first reported a position in GSK in Q4 2023 and has held it in 10 quarters since. The position peaked at $332K in Q1 2024. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Bruce G. Allen Investments held 5,551 shares of GSK worth $306K as of Q1 2026.
  • Bruce G. Allen Investments sold 204 GSK shares in Q1 2026, an estimated $11.1K.
  • GSK made up 0.2% of Bruce G. Allen Investments's portfolio in Q1 2026, its #54 holding.
  • Bruce G. Allen Investments first reported a position in GSK in Q4 2023 and has held it in 10 quarters since.
  • Bruce G. Allen Investments's GSK position peaked at $332K in Q1 2024.
  • 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Bruce G. Allen Investments's 13F filing for Q1 2026, filed 8 May 2026.